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Sirtuin 4 reveal isoform-specific acyl recognition
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Sirtuins are evolutionary conserved NAD+-dependent protein lysine deacylases. The seven
human isoforms, Sirt1-7, regulate metabolism and stress responses and are considered
therapeutic targets for aging-related diseases. Sirt4 locates to mitochondria and regulates
fatty acid metabolism and apoptosis. In contrast to the mitochondrial deacetylase Sirt3 and
desuccinylase Sirt5, no prominent deacylase activity and structural information are available
for Sirt4. Here we describe acyl substrates and crystal structures for Sirt4. The enzyme
shows isoform-specific acyl selectivity, with significant activity against hydro-
xymethylglutarylation. Crystal structures of Sirt4 from Xenopus tropicalis reveal a particular
acyl binding site with an additional access channel, rationalizing its activities. The structures
further identify a conserved, isoform-specific Sirt4 loop that folds into the active site to
potentially regulate catalysis. Using these results, we further establish efficient Sirt4 activity
assays, an unusual Sirt4 regulation by NADH, and Sirt4 effects of pharmacological
modulators.
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Reversible acetylation of protein Lys side-chains is a post-translational modification in all domains of life. More than7000 mammalian acetylation sites are known, and many of
them regulate various target functions1,2. Among the protein Lys
deacetylases, sirtuins form the evolutionary defined class III. They
catalyze an unusual, NAD+-dependent deacetylation reaction,
coupling their activity to the metabolic state3. The seven mam-
malian sirtuin isoforms are primarily located in nucleus (Sirt1, 6,
7), cytosol (Sirt2), or mitochondria (Sirt3, 4, 5), and they regulate
processes from metabolism to stress responses2,4. Sirtuins have
further been implicated in aging-related diseases, such as meta-
bolic disorders and neurodegeneration, and are considered
potential therapeutic targets5,6.
Sirt4 acts as a metabolic regulator. It inhibits malonyl-CoA-
decarboxylase (MCD), which represses fatty acid oxidation and
promotes lipid anabolism6,7, and it inhibits pancreatic glutamate
dehydrogenase (GDH) to regulate insulin secretion8,9. Sirt4 fur-
ther inhibits pyruvate dehydrogenase (PDH)10 and stimulates
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Fig. 1 Sirt4 deacylation activities. a Chemical structures of CPS1 peptide and Lys acylations; from top: acetylation, butyrylation, DMS-ylation, HMG-
ylation. For the complete set of acyl modifications see Supplementary Fig. 1a. b Sirt4-dependent deacylation of differently acylated CPS1 peptides. (n= 2;
error bars: s.d.). c Sirt4 titrations with CPS1 substrate peptide carrying an acetyl, lipoyl, HMG, or DMS modification, respectively. (n= 2; error bars: s.d.). d
Comparison of Sirt3, 4, and 5 deacylation activities against substrate peptide with acetyl, succinyl, DMS, or HMG modification, respectively. (n= 2; error
bars: s.d.). e Intact protein mass spectrometry of HMG-ylated CypA (unmodified molecular weight 18,012 Da). f Sirt4-dependent deacylation reactions
with increasing amounts of untreated and HMG-ylated CypA protein, respectively, as a substrate. (n= 2; error bars: s.d.). g Comparison of the acyl
selectivities of Sirt4 from human (hSirt4), clawed frog (xSirt4), and zebrafish (zSirt4) using CPS1 peptide substrates featuring an acetyl, succinyl, DMS,
itaconyl, HMG, or lipoyl modification, respectively. (n= 2; error bars: s.d.)
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mitochondrial ATP production11. Due to these effects on energy
metabolism, Sirt4 is considered a therapeutic target for metabolic
dysfunctions6,7. Furthermore, Sirt4 displays tumor suppressor
activity through downregulation of glutamine metabolism and
has been implicated in several cancer types6,12.
Sirtuins are increasingly recognized as deacylases with isoform-
specific acyl selectivities, catalyzing removal of acylations emer-
ging as posttranslational protein modifications, such as succiny-
lation or crotonylation13–15. While Sirt1–3 are strong
deacetylases, Sirt5 shows low-deacetylation activity and acts pri-
marily as a desuccinylase and deglutarylase13,15,16, and Sirt6
deacetylates histones but displays more prominent demyr-
istoylation activity17. Similarly, Sirt4 features weak deacetylation
activity, which appears to regulate MCD7, but for most of its
functional effects the catalyzed target modification appears to
differ or is unknown6. It can inhibit PDH through delipoyla-
tion10, but the catalytic efficiency for this reaction appears much
lower than for other primary sirtuin activities13. ADP-
ribosyltransferase activity was also described for Sirt4 and Sirt6,
but it is also inefficient and appears to constitute a side-
activity8,18, so that a prominent Sirt4 enzyme activity remains to
be identified.
Sirtuins share a conserved catalytic core of ~275 amino acids19.
Isoform-specific N-terminal and C-terminal domains contribute
to regulation and cellular localization6,20. In Sirt4, the core has no
C-terminal appendage and only a short, ~28 residue N-terminal
extension that serves as mitochondrial localization sequence6,9.
The sirtuin core comprises a Rossmann-fold subdomain and a
smaller Zn2+-binding module21,22. NAD+ and the acylated sub-
strate polypeptide are bound, with moderate sequence selectivity,
to a cleft between the subdomains, accompanied by closure
movements of the subdomains and a flexible “cofactor-binding
loop”1,21–24. The ribose then releases nicotinamide (NAM), and
via an 1′-O-alkylimidate and a bicyclic intermediate the products,
deacetylated polypeptide and 2′-O-acyl-ADP-ribose, are
formed3,19. This mechanism was deduced from biochemical
studies and crystal structures including human Sirt1, 2, 3, 5, and
63,19,21,22,25,26, and it applies to all sirtuin-dependent deacyla-
tions. The isoform differences in preferred substrate acyls are
caused by binding of the acyl moiety to an active site channel with
isoform-specific features. For Sirt4, however, a lack of structural
and enzymatic data hampers insights in Sirt4 acyl specificity and
regulation.
Here we report crystal structure and enzymatic characteriza-
tion of Sirt4. We identify an evolutionary conserved, Sirt4-specific
acyl selectivity and dehydroxymethylglutarylation (de-HMG-
ylation) as a potential physiological activity. A structure of Sirt4
from X. tropicalis reveals an unusual acyl binding site and a Sirt4-
specific, potentially regulatory loop. Using these insights, we
analyze and rationalize Sirt4 modulator effects and identify a Sirt4
regulation by NADH.
Results
Sirt4 shows an isoform-specific acyl preference. The seven
mammalian sirtuins vary in their sequence and acyl pre-
ferences16,19. The Sirt4 deacylation activities reported so far,
deacetylation and delipoylation, were weak, with orders of mag-
nitude lower kcat/KM values as for other sirtuin/substrate acyl
pairs7,10,15. Testing ~6800 mammalian acetylation site sequences
yielded no dramatic activity improvements1. We therefore asked
whether other acyl modifications would yield deacylation effi-
ciencies expected for a physiologically dominant Sirt4 activity.
Testing Sirt4 against an acyl library of CPS1 (carbamoyl phos-
phate synthetase 1)-Lys527 peptides in a coupled enzymatic assay
monitoring NAM release from NAD+ 27 indeed revealed a
particular specificity profile (Fig. 1a, b, Supplementary Fig. 1a).
Consistent with previous reports1,7,10, Sirt4 showed low-
deacetylation activity but higher activity against lipoylated and
biotinylated substrate (Fig. 1b). Further increased activity was
obtained with butyryl and octanoyl substrate, but the highest
activity—eightfold stronger than deacetylation—was observed
with a 3,3-dimethylsuccinyl (DMS) substrate.
Comparing DMS to acyl moieties physiologically occurring as
activated CoA-thioesters, and thus potentially modifying protein
Lys side chains28,29, revealed the 3-hydroxy-3-methylglutaryl
(HMG) group as most closely related. Testing HMG-modified
CPS1-Lys527 peptide indeed yielded Sirt4 activity similarly to
DMS-CPS1 substrate (Fig. 1b), approximately threefold higher
than for acetyl peptide and with the expected NAD+ dependency
(Supplementary Fig. 1b). To analyze the mechanistic basis of
these differences, we compared through Michaelis-Menten
kinetics the improved substrates, HMG- and DMS-CPS1, with
lipoyl- and acetyl-CPS1 (Fig. 1c, Table 1). Consistent with
previous data10,16, catalytic efficiency kcat/KM for acetyl-CPS1 was
low (3.7± 0.7 M−1 s−1; Table 1). Sirt4 activity was strongly
increased for DMS-CPS1 (412± 41M−1 s−1) and HMG-CPS1
(546± 67M−1 s−1). Strikingly, the preferred acyls showed com-
parable turnover rates to acetyl substrate but increased apparent
affinities (two orders of magnitude lower KM; Fig. 1c, Table 1).
Interestingly, lipoyl-CPS1 yielded an only slightly lower kcat/KM
(170± 230M−1 s−1), two orders of magnitude higher than a
previously published value10, due to a better KM in our study,
comparable to those for the DMS/HMG modifications (Table 1).
These results indicate that lipoylated substrates bind much better
to Sirt4 than so far known, but DMS/HMG still yield 3–5-fold
higher efficiencies due to faster turnover. Importantly, the
catalytic efficiencies with the DMS/HMG substrates are close to
those of robust sirtuin activities, such as Sirt2-dependent
deacetylation (e.g., 1400M−1 s−1 for histone H3-K2730). Sirt4
thus features significant deacylation activity and appears to
discriminate acyl substrates mainly via their apparent binding
affinity.
Sirtuin-dependent NAM release from NAD+ is normally
coupled to deacylation. However, when we analyzed Sirt4-
dependent turnover of HMG-CPS1 through MS detection of
substrate and product peptide parallel to monitoring NAD+
hydrolysis, HMG-CPS1 deacylation corresponded only to ~40 %
of the NAD+ turnover (Supplementary Fig. 1c). For Sirt4-
dependent conversion of acetyl-CPS1, in contrast, no discrepancy
to NAD+ hydrolysis was observed (Supplementary Fig. 1c). Sirt4
thus shows significant NAD+-dependent de-HMG-ylation activ-
ity, but it catalyzed even slightly better HMG-stimulated NAD+
glycohydrolysis as an unusual, deacylation independent sirtuin
activity.
We next compared the selectivities of the mitochondrial
sirtuins Sirt3, 4, and 5 against CPS1 peptides carrying HMG-
modifications and DMS-modifications or the generic Sirt3 and
Table 1 Kinetic parameters for Sirt4 and acyl substrates
kcat (10−3 s−1) KM (μM) kcat/KM (M−1 s−1)
Acetyl-CPS1 8.7± 0.7 2341± 270 3.7± 0.7
Acetyl-DLATa NDa ND (>2500)a 0.2± 0.0 (estimated)a
Lipoyl-CPS1 1.7± 0.3 10.1± 13.6 170± 230
Lipoyl-DLATa 1.8± 0.1a 239± 51a 7.7± 1.3a
DMS-CPS1 7.3± 0.1 17.7± 1.5 412± 41
HMG-CPS1b 5.3± 0.1 9.7± 1.0 546± 67
aValues from10
bNot corrected for HMG-stimulated NAD+ hydrolysis
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5 substrate modifications acetylation (Sirt3) and succinylation
(Sirt5). Sirt4 showed the previous preference for DMS and HMG
modifications, and very low-activity against acetylated or
succinylated peptide (Fig. 1d). Sirt3, in contrast, featured
pronounced selectivity for the acetyl modification, minor activity
against DMS substrate, and no turnover with HMG and succinyl
substrate (Fig. 1d). The other way round, Sirt5 showed no activity
against acetyl substrate but high activity against succinyl peptide,
and lower but still significant activity against DMS- and HMG-
CPS1 consistent with reported parameters for HMG substrate
(KM= 8 μM, kcat/KM= 500M−1 s−1)15. Sirt5 activity against
HMG-CPS1 thus exceeds that of Sirt4 mainly due to faster
turnover, and this Sirt5 activity appears even higher with other
peptide sequences, but it is still 60–80% lower than the enzyme’s
desuccinylase activity (Fig. 1d). In summary, Sirt4 shows a
particular acyl preference profile: it shares de-HMG-ylation but
no desuccinylation activity with Sirt5 and shows no activity
overlap with Sirt3, and it features unusual activity against DMS
substrate and for HMG-stimulated NAD+ hydrolysis. This
distinct profile suggests that there might be additional protein
Lys acylations that are specifically removed by Sirt4.
HMG-CoA acylates and Sirt4 de-HMG-ylates proteins. Acetyl
transferases employ acetyl-CoA for modifying proteins. However,
acetyl-CoA can also non-enzymatically modify proteins, and
some other acyl-CoA, such as succinyl-CoA, do so even more
efficiently, likely causing the emerging variety of protein acyla-
tions14,28,29,31. We thus analyzed whether HMG-CoA efficiently
acylates peptides and proteins. HMG-CoA titrations revealed
CPS1 peptide acylation with a bimolecular rate constant of (4.0±
0.8)×10–10 μM−1 s−1, more than twice as fast as with acetyl-CoA
(k= (1.5± 0.4)×10–10 μM−1 s−1)29, in agreement with a recent
study reporting more efficient protein acylation by glutaryl- and
HMG-CoA as compared to acetyl-CoA28. Incubating recombi-
nant Cyclophilin A (CypA) as a model protein with HMG-CoA
resulted in 1–7 HMG-modifications as detected by intact protein
mass spectrometry (MS; Fig. 1e) and confirmed by MS/MS
analysis of tryptic peptides, consistent with the protein’s seven
known Lys acetylation sites (Uniprot entry P62937).
To analyze whether Sirt4 is able to remove HMG modifications
not only from peptides but also from HMG-ylated protein, we
tried to de-HMG-ylate CypA. Modified and unmodified CypA
was incubated with Sirt4, in the presence and absence of NAD+,
and the deacylation was monitored in the coupled enzymatic
assay27. Unmodified CypA as substrate did not yield a significant
deacylation signal, whereas HMG-CypA substrate resulted in a
strong, substrate concentration dependent signal (Fig. 1f) that
showed the expected dependency on the co-substrate NAD+
(Supplementary Fig. 1d). To confirm that NAD+-dependent
CypA de-HMG-ylation causes or significantly contributes to the
NAM release monitored in this assay, we also analyzed the
reaction by intact protein mass spectrometry. Incubation with
Sirt4 indeed caused a shift toward CypA species carrying fewer
HMG-ylations (Supplementary Fig. 1e), confirming the deacyla-
tion. We thus conclude that HMG-CoA is reactive toward
proteins and that Sirt4 can de-HMG-ylate the modified proteins,
consistent with recently published work that furthermore
confirmed the physiological occurrence of protein HMG-ylation
and Sirt4-dependent de-HMG-ylation28,32.
Crystal structure of Sirt4. For insights in the molecular basis of
Sirt4’s substrate preference and other isoform-specific features,
we solved a Sirt4 crystal structure. Trials to crystallize our human
Sirt4 protein construct (residues 25–314), which comprises the
catalytic core with native C-terminus but lacks 24 residues of the
N-terminal mitochondrial localization sequence (MLS; residues
1–289), were not successful. Therefore, we used the Sirt4 ortho-
logues from Xenopus tropicalis (clawed frog; xSirt4) and Danio
rerio (zebrafish; zSirt4) as model systems. They show significant
sequence deviations only in the ~30 N-terminal residues (Sup-
plementary Fig. 2a), consistent with their function as MLS, which
tend to show low-sequence conservation33. Within the catalytic
core (hSirt4: 32–312; xSirt4: 31–314; zSirt4: 28–310), however, the
sequence identity with hSirt4 is 67% (xSirt4; similarity 81%) and
Table 2 Data collection and refinement statistics
xSirt4/ADPr xSirt4/thioacetyl-ADPr zSirt5/HMG-CPS1
Space group C2221 C2221 P6522
Unit cell constants a= 69.4 Å, b= 74.7 Å, c= 109.7 Å a= 69.0 Å, b= 74.9 Å, c= 109.6 Å a= b= 87.5 Å, c= 316.9 Å
Resolutiona 20.00–1.58 Å (1.62–1.58 Å) 20.00–1.80 Å (1.85–1.80 Å) 50.00–3.10 Å (3.20–3.10 Å)
Unique reflections 39,280 (2868) 26,585 (1932) 13,919 (1214)
Multiplicity 5.1 (5.2) 6.8 (7.1) 10.3 (10.8)
Completeness 99.8% (99.9%) 99.7% (99.9%) 99.9% (99.9%)
Rmeas 3.6% (85.3%) 5.5% (104.4%) 24.8% (151.2%)
CC1/2 (%) 100.0 (70.4) 99.9 (70.4) 99.4 (59.8)
I/σI 23.7 (2.1) 18.3 (2.1) 10.2 (1.6)
Protein atoms 2285 2177 4138
Ligand atoms 37 40 173
Solvent atoms 285 179 68
Resolution 19.73–1.58 Å (1.62 Å – 1.58 Å) 19.74–1.80 Å (1.85–1.80 Å) 48.67–3.10 Å (3.18–3.10 Å)
Rcryst/Rfreebc 15.2%/18.6% 15.5%/20.8% 19.6%/26.6%
Average B-factors
Protein 30.9 39.4 73.4
Ligands 21.8 30.4 74.3
Solvent 41.6 46.3 48.5
RMSD bond-lengths 0.03 0.03 0.01
RMSD bond-angles 2.6 2.4 1.5
aValues in parentheses refer to outermost shell
b Rcryst ¼
P
Fobsj jkj jFcalc jjP
Fobsj j . |Fobs| is the observed and |Fcalc| the calculated structure factor amplitude
cRfree was calculated from 5% of reflections omitted from refinement
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65% (zSirt4; similarity 78%), respectively (Supplementary Fig. 2a).
Consistent with the high sequence conservation, xSirt4 and
zSirt4 showed the same acyl preferences as hSirt4 (Fig. 1g),
confirming that this acyl selectivity is an evolutionary conserved
Sirt4 feature and that xSirt4 and zSirt4 are suitable models for the
mammalian enzyme.
xSirt4 yielded well diffracting crystals in presence of ADP-
ribose (ADPr). The xSirt4/ADPr structure was solved through
Patterson searches with Sir2Af1 (PDB entry 4TWI) and refined at
1.58 Å resolution to Rcryst/Rfree values of 15.2%/18.6% (Table 2).
The xSirt4 overall structure shows the typical sirtuin architecture
with Rossmann-fold domain and smaller Zn2+-binding module,
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Fig. 2 Crystal structure of xSirt4. a Overall structure of the xSirt4/ADPr complex, with Rossmann-fold domain (green), Zn2+-binding domain (cyan), and a
Sirt4-specific loop (blue) indicated. ADPr is shown as sticks, colored according to atom type. Secondary structure elements are numbered equivalent to
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region in Sirt4 sequences from various chordates (Full alignment: Supplementary Fig. 2c). d Section of a structure-based alignment of Sirt1–6, extended by
chordate Sirt1–7 sequences, showing the isoform differences in the Sirt4-loop region (Full alignment: Supplementary Fig. 2d). e Overlay of xSirt4 (gray,
blue) with Sirt3 (light gray, red; PDB ID 4BVH) and 5 (dark gray, orange; 4G1C) showing the extended Sirt4-loop, the shorter Sirt5 surface loop, and the
short turn in Sirt1–3 (represented by Sirt3)
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with the active-site located in between them and harboring the
nucleotide that is well defined by electron density (Fig. 2a, b). The
six-stranded β-sheet of the Rossmann-fold domain provides a
docking patch for the nucleotide, orienting the reacting ribose
close to the conserved catalytic sirtuin residue His160 (Fig. 2b;
numbering refers to xSirt4 if not stated otherwise). Due to the
occupied nucleotide binding site, the cofactor-binding loop
between α2 and α3 is in the “closed” conformation23, positioning
the conserved Phe/Tyr (Tyr73) on top of the ADPr ribose.
Thermal denaturation shift experiments showed significant
Sirt4 stabilization by NAD+ or ADPr, while substrate peptide
and NAM had no pronounced effects (Supplementary Fig. 2b),
indicating that the nucleotide-induced closed conformation
stabilizes the protein and facilitates crystallization.
A Sirt4-specific loop and additional active site entry. Com-
paring the Sirt4 structure to other sirtuin isoforms reveals as most
striking difference an extended, ~12 residues Sirt4 loop in the
Zn2+-binding module, between α8 and α9 (residues 195–206;
Fig. 2a). The loop is oriented deep into the catalytic core and
contributes to the active site lining (Fig. 2b). A sequence com-
parison of all higher eukaryotic Sirt4 orthologs in the UNIPROT
database shows a high overall sequence homology (89%), and in
particular a strict conservation of the presence and even sequence
of this loop (G(L/V)APDGDVFL(T/S)(D/E)EQ motif; Fig. 2c,
Supplementary Fig. 2c). Structure-based comparison of human
Sirt1–6, with human Sirt7 and Sirt1–7 sequences from other
chordates added based on homology, shows that the loop is
absent in all other sirtuin isoforms (Fig. 2d, Supplementary
Fig. 2d), and we therefore refer to it as “Sirt4-loop”. The
structure-based comparison shows that the Sirt4-loop is extended
compared to a much smaller Sirt5 surface loop, and to a short
turn in other isoforms, and only the Sirt4-loop is thus able to
reach the active site (Fig. 2b, e). Removing the loop (Δ189–214
and Δ192–212) yielded insoluble protein, but deleting the loop’s
core (Δ196–205, Δ198–203) or replacing it with a GSS linker
(Δ196–205 + GSS) resulted in soluble and active protein, which
shows that the extended loop is not essential for Sirt4’s structural
integrity. The variants tended to show higher KM values for the
peptide substrate and at the same time slightly increased turnover
(Table 3), which indicates that the loop contributes to substrate
binding and restricts catalytically relevant active site dynamics
(see also below). In a second xSirt4 structure, solved in complex
with the product analog 2′-thioacetyl-ADPr, the Sirt4-loop was
not defined by electron density (Table 2, Supplementary Fig. 2e),
indicating that it is either flexible or can assume several con-
formations. Both xSirt4 complexes were solved from the same
crystal form, with residues 191–207 not participating in crystal
contacts, excluding that crystal packing causes the loop differ-
ences. The Sirt4/2′-thioacetyl-ADPr structure might thus suggest
that the loop is released from the active site during product
formation, but functions and triggers of Sirt4-loop conformations
remain to be studied in more detail.
Another unusual feature of the Sirt4 catalytic core is a channel
that branches off from the acyl-Lys binding tunnel and leads to
the protein surface (Fig. 3a, b). It is lined by residues from α4 and
the preceding loop (86-ArgArgProIle, Glu93), α5 (Ala100, 103-
ArgTyr, Arg107), and Ala199/Asp203 from the Sirt4-loop
(Fig. 3a). They are mostly conserved in Sirt4, but differ in other
isoforms (Fig. 3b). In Sirt6, the Sirt4 channel area is blocked by its
isoform-specific N-terminus, but lack of α4, part of α5, and both
loops results in a differently oriented, wide cleft that accom-
modates myristoyl substrates and activators34. Sirt1–3 and Sirt5
contain structure elements sized comparable to Sirt4, except for
the missing Sirt4-loop, with sequences similar to each other but
differing from Sirt4 (Fig. 3b, Supplementary Fig. 2d). The
resulting fold in Sirt1–3 and Sirt5 comprises a more wiggled
α3/α4 loop folded against α5 and blocking the Sirt4 channel area
(Supplementary Fig. 3a). The Sirt4 channel has a small positively
charged patch at the outer entrance but is generally rather
hydrophobic, and we speculate that it contributes to accommo-
dation of longer substrate acyls. Modeling a Sirt4/lipoyl-Lys
complex indeed places the distal lipoyl end into the bottom of the
channel (Fig. 3a), supporting an acyl binding function and
rationalizing Sirt4’s delipoylation activity. Interestingly, the
channel could also accommodate a lipoyl group entering from
outside as a substrate anchor, in a scenario related to SirTM,
which catalyzes ADP-ribosylation of targets only after their
lipoylation35. Furthermore, the channel might serve as a binding
site for regulatory metabolites, similar to Sirt6 activation by free
fatty acids16. Testing the effects of fatty acids, lipoic acid, and the
ketone bodies beta-hydroxybutyrate and acetoacetate indeed
revealed that free lipoic acid inhibits Sirt4’s deacetylation and
de-HMG-ylation activity (Supplementary Fig. 3b). However, the
role of the Sirt4 channel in this and/or other regulation
mechanisms remains to be studied in detail.
Using our structure-based alignment of Sirt4 and other
structurally characterized sirtuins, extended by chordate
Sirt1–7 sequences (Fig. 2d, Supplementary Fig. 2d), we analyzed
phylogenetic relationships. The phylogenetic tree (based on
208 sequences; Fig. 3c) confirms some classifications based purely
on sequence information36 but also reveals modifications. Sirt4
forms a separate class (class II in ref. 36) that is almost equally
distant to classes I (Sirt1–3), III (Sirt5), and IV (Sirt6/7), despite
its partial deacylation activity overlap with Sirt5. Prokaryotic
Table 3 Kinetic parameters for xSirt4 wild-type and variantsa
xSirt4 variant Acetyl-CPS1 KM (μM) Acetyl-CPS1 vmax (10−3 s−1) HMG-CPS1 KM (μM) HMG-CPS1 vmax (10−3 s−1)
Wild-type 663± 69 12.9± 0.6 6.8± 0.9 15.9± 0.4
Delta 196–205 + GSS 541± 51 10.7± 0.4 9.7± 0.7 18.4± 0.3
Delta 196–205 1599± 563 15.7± 3.4 8.5± 0.6 17.2± 0.2
Delta 198–203 1104± 110 17.1± 0.9 10.1± 0.7 19.9± 0.3
D201A 707± 127 9.1± 0.8 11.3± 1.4 13.0± 0.3
D203A 925± 136 10.5± 0.8 9.0± 1.1 14.1± 0.3
Y73F 640± 71 8.8± 0.4 9.0± 1.0 24.1± 0.5
R101A ND ND 23.2± 1.3 13.3± 0.2
Y104F 643± 40 13.3± 0.4 15.3± 1.3 15.2± 0.3
R107A 1097± 159 11.0± 0.9 17.2± 1.8 14.2± 0.3
Y104F R107A 918± 72 18.5± 0.8 22.6± 2.6 15.7± 0.4
N108A 1104± 254 14.8± 1.9 19.3± 2.8 12.2± 0.4
aNot corrected for HMG-stimulated NAD+ hydrolysis
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sirtuins form a cluster in the Sirt5 branch, separate from chordate
Sirt5 and almost equidistant to Sirt4. The Sirt6/7 branch also
comprises a prokaryotic member, Sir2Tm. The three subclusters
for the strong deacetylases Sirt1, 2, and 3 are clearly separated
from the other branches but contain yeast enzymes, indicating
that a deacetylase developed still early during evolution and
diversified further, possibly reflecting the prominent role of
acetylation among the protein acylations. All other branches
appear to constitute subfamilies with mostly weak deacetylases,
which developed different acyl preference profiles for each cluster
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that remained conserved in later stages of evolution as indicated
by our Sirt4 ortholog comparison. These major branches
apparently separated early during evolution, consistent with a
variety of acylations occurring non-enzymatically28,29,31 and thus
likely being evolutionary early posttranslational modifications
that existed before the protein modifying enzymes emerged.
Sirt4 nucleotide and acyl binding sites. All sirtuins share NAD+
as an essential cosubstrate, but the Sirt4 nucleotide binding site
differs from those of other isoforms. The Sirt4-loop tightens the
entry of the C-site, where the conserved Asp145 recognizes the
NAM moiety of NAD+25, and its tip around Pro200 will have to
rearrange slightly to allow productive NAD+ binding (Supple-
mentary Fig. 3c), consistent with a switch function. However,
NAD+ titrations revealed similar apparent NAD+ affinities for
wild-type Sirt4 (KM= 70± 14 μM for xSirt4; 62± 14 μM for
hSirt4) and a Sirt4 loop deletion variant (KM= 66± 9 μM; Sup-
plementary Fig. 3d), suggesting that a regulatory factor stabilizing
the inactive conformation might be missing, consistent with the
loop variability observed in our structures (see above). Positive
electrostatic potential in the nucleotide site supports binding of
the negatively charged ligand in all isoforms, but in Sirt4 the
positive potential is more pronounced than in most isoforms
(Fig. 3d, Supplementary Fig. 3e), rationalizing its low KM(NAD+)
within the 14–600 μM range reported for sirtuins15,37,38. Sirt4’s
cosubstrate site might also facilitate binding of NADH, compared
to NAD+, due to its lacking positive charge at the nicotinamide,
and we indeed find a distinctive sensitivity of this sirtuin isoform
to NADH (see below). In the peptide binding cleft, Sirt4 also
features positive potential in regions accommodating the sub-
strate sequence immediately N-terminal and C-terminal from the
substrate acyl-Lys (Supplementary Fig. 3f). Consistently, peptide
array studies with its weaker deacetylase activity had shown a
Sirt4 substrate sequence preference for polar residues around the
acetyl-Lys, in particular with negative charges in positions +1/2
and −3/41.
In the active site, Sirt4 comprises the conserved sirtuin catalytic
residues His160 and the Leu/Thr/Val (Thr231) whose backbone
oxygen orients the substrate through a hydrogen bond to the acyl-
Lys ε-amide (Fig. 2b)15. The cofactor-binding loop in “closed”
conformation23 positions the conserved Phe/Tyr (Tyr73) on top
of the ribose, shielding this reacting group. Mutating Tyr73 to the
Phe found in most sirtuins increased kcat (Table 3), confirming its
catalytic relevance and indicating that its hydroxyl group might
contribute to an auto-inhibitory mechanism. In the region
accommodating a distal carboxyl group in short and medium
long dicarboxylates, such as HMG, mildly positive electrostatic
potential rationalizes the affinity of such substrates (Fig. 3d).
Attempts to solve a Sirt4 structure in complex with substrate
peptide to study acyl recognition details failed, possibly due to the
lacking stabilization by this ligand (Supplementary Fig. 2b), but
we were able to solve a complex of zebrafish Sirt5 (zSirt5) with
HMG-CPS1 peptide. The structure, refined at 3.1 Å resolution to
Rcryst/Rfree values of 19.5%/26.6% (Table 2, Fig. 3e), reveals a
similar substrate conformation as in zSirt5/glutaryl-CPS1. The
HMG length is reduced through a helical conformation, albeit
with opposite handedness compared to glutaryl-CPS1, to position
the 3-hydroxy and 3-methyl moieties toward Ile138/His154 and
Tyr98/Val216, respectively (Fig. 3e, Supplementary Fig. 3g). The
distal carboxylate interacts with Tyr98 and Arg101, which also
recognize the carboxylates of succinyl and glutaryl substrates15.
Interestingly, Sirt4 also features such a Tyr-X-X-Arg motif in α5.
The Sirt4 motif is shifted one helix turn, however, with Sirt4-
Tyr104 oriented back to the region occupied by Sirt5-Tyr98, but
Sirt4-Arg107 pointing away from the acyl channel (Fig. 3f). Sirt4
residues in the positions of Sirt5-Tyr98/Arg101 would be Asn108
and Gly111. Due to a slightly different conformation, however,
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Gly111 is shifted and the area of Sirt5-Arg101 is occupied by the
Sirt4-loop residue Asp201 (Fig. 3f), which would result in close
contacts between the carboxylates of Asp201 and an HMG
substrate. To test the roles of these residues, we analyzed
deacetylation and de-HMG-ylation kinetics of xSirt4 Ala variants
(Table 3). Exchanging Asp201 or Asp203 caused only a moderate
decrease in apparent HMG-peptide affinity, consistent with Sirt4-
loop deletion effects. They thus appear not directly involved in
substrate binding but to rearrange dynamically, as expected from
the repellent effect Asp201 would have on substrate carboxylates
and in line with our crystallographic results. Consistently, testing
β-Ala-, γ-aminobutyryl-, and 6-aminocaproyl-CPS1 substrates
(Supplementary Fig. 1a), which have positively charged end
groups that could favorably interact with Asp201 in this position,
yielded no Sirt4-dependent deacylation (Supplementary Fig. 3h).
Replacing Tyr104 (to Phe) or Arg107 of the Sirt4 Tyr-X-X-Arg
motif had a stronger, approximately twofold effect on HMG-
peptide KM values, and a Tyr104Phe/Arg107Ala double mutant
even showed an additive effect (Table 3). They thus seem to
contribute—directly or indirectly—to substrate binding despite
Arg107’s orientation away from the active site. In fact, replacing
the neighboring Asn108, which points toward the acyl channel,
caused a significant, approximately threefold decrease in apparent
HMG-substrate affinity, suggesting a contribution to acyl binding
and possibly an indirect role for Arg107, via its salt bridge to the
Sirt4-loop residue Asp203 (Fig. 3f). Interestingly, mutating
Arg101 from a 101-ArgArgArg-103 motif on the opposite side
of Tyr104 caused a strong, approximately fourfold decrease in
apparent HMG-peptide affinity (Table 3), indicating an impor-
tant role in substrate recognition despite its distance to the acyl
site. These results indicate that as in Sirt5, α5 plays a key role in
Sirt4 acyl recognition. Residue differences seem to contribute
directly to their different acyl selectivity profiles, but also to a
more dynamic Sirt4 acyl site, which we speculate to adapt to acyl
substrates (α5 N-terminus) and to contribute to a regulatory
Sirt4-loop function (α5 center).
Sirt4 substrates and structure enable modulator studies. Our
insights in Sirt4 catalytic activity and structure now enable
activity studies for Sirt4 modulator development and a structure-
based analysis of compound effects. Using the HMG-CPS1 pep-
tide, we analyzed the effects of the Sirt1 activators resveratrol and
SRT172039,40, the moderately Sirt1 selective inhibitors Ex527 and
sirtinol25,41, and the pan sirtuin inhibitor suramin42,43. At 10 and
100 μM compound concentration, respectively, there was no
significant effect for resveratrol, Ex527, and sirtinol (Fig. 4a).
Suramin caused potent Sirt4 inhibition, similar to its effects on
other sirtuin isoforms42,43, and 100 μM SRT1720 led to a weak
signal decrease but with a high error and significant effect already
in a control reaction, indicating a compound incompatibility with
the coupled enzymatic assay used here. Suramin is a huge poly-
anionic compound occupying the complete active site of sirtuins
and other targets44. Ex-527, in contrast, is accommodated by a
small region around the C-site25, and an overlay of Sirt3/Ex-527
with our Sirt4 structure rationalizes Sirt4’s insensitivity (Fig. 4b):
The compound would clash with its A ring with Pro200 from the
Sirt4-loop, and omitting the A ring and instead attaching the
carbamide via a methylene group to ring B might yield a Sirt4-
specific compound.
As a convenient and complementary, fluorescence-based
alternative to the coupled enzymatic assay with HMG-peptides,
we established substrate and assay corresponding to the popular
“Fluor-de-Lys” (FdL) deacylation assays19. Attaching the HMG
group to a Lys with Z-protected amino group and 7-
aminomethylcoumarin (AMC) coupled to the carboxyl group,
analog to the Sirt1–3 acetyl substrate Z-MAL45, yielded an HMG-
FdL substrate readily accepted by Sirt4 and sensitively monitored
via fluorescence using the FdL procedure19. Testing suramin with
the HMG-FdL substrate confirmed the potent Sirt4 inhibition
observed in the coupled enzymatic assay (Fig. 4c), and a dose-
response experiment yielded an IC50 of 1.8± 0.2 μM (Supple-
mentary Fig. 4a). Assays with SRT1720 showed no incompat-
ibilities in control reactions and revealed that the compound has
no effect on Sirt4 activity (Fig. 4c). We then employed the FdL-
like Sirt4 assay for studying the effects of NAM and NADH,
which are not compatible with the coupled assay. NAM appears
to act as a physiological regulator for most sirtuin isoforms37, and
a NAM dose-response experiment with Sirt4 revealed potent
inhibition with IC50= 13± 2 μM (Fig. 4d). The effect on Sirt4 is
even more potent than on other isoforms37,46 and possibly
supported by the Sirt4-loop at the NAM accommodating C-site
entrance. An NADH dose-response experiment (Fig. 4e), cor-
rected through NADH spiking controls for its fluorescence
overlap with AMC47, also indicated pronounced Sirt4 inhibition
(IC50= 126± 12 μM at 500 μM NAD+). Analyzing the NADH
titration with the robust MS assay confirmed this Sirt4 inhibition
potency (IC50= 142± 54 μM; Supplementary Fig. 4b) that
exceeds NADH effects on other sirtuins (IC50 1.3–27.9 mM)
47,48, consistent with Sirt4 nucleotide site features (see above and
discussion). The response of Sirt4 activity to NADH levels around
~30 μM, which is estimated to be the mitochondrial concentra-
tion of free NADH47, suggests NADH or the NAD+/NADH ratio
to act as a physiological Sirt4 regulator.
Discussion
Posttranslational modifications are a ubiquitous mechanism of
protein regulation and rely on activated metabolites, which are
now realized also to cause non-enzymatic modifications14,28,29,49.
For emerging acyl modifications, such as succinylation and cro-
tonylation, acyl-CoAs act as major activated metabolites14 whose
concentrations thus influence modification levels, together with
deacylating enzymes. Elevated HMG-CoA levels in a HMG-CoA-
Lyase deficiency model indeed increased protein HMG-ylation28,
and similar changes are expected under fasting conditions and
during ketogenic protein catabolism, suggesting that de-HMG-
ylating enzymes will regulate target functions during starvation.
Sirtuins convert several acyl substrates but with isoform-specific
selectivity profiles15,38, and we find that Sirt4 also has a particular
acyl preference profile. It shares de-HMG-ylation activity with
Sirt5 but they differ, e.g., in their desuccinylase activity, and
Sirt3–5 might have developed complementary selectivities to
cover a range of acyls reflecting the variety of activated metabo-
lites in mitochondria. Sirt5’s higher de-HMG-ylation activity
might suggest that other, even better Sirt4 substrate acyls might
exist, but also shared deacylation activities can be complementary
due to sirtuin differences in substrate sequence preference and
tissue distribution1,50. The substrate acylations might be acci-
dental “damage”, which would render sirtuins repair enzymes,
but many of them regulate dedicated target functions, consistent
with specific regulatory effects of sirtuins4,6. The additional
HMG-dependent NAD+ hydrolase activity of Sirt4 could serve a
signaling function, similar to NAD+ depletion caused by poly-
(ADP-ribose) polymerases, but a functional role of this unusual
sirtuin activity remains to be studied further.
Sirtuin isoforms differ in acyl channel architecture and
dynamics. Sirt5 provides a rather rigid binding site for succiny-
lations, but related dicarboxylate modifications can adapt to this
site, rationalizing Sirt5’s activity against glutarylations15,51 and
HMG-ylations (present study). Sirt6, in contrast, has a long,
hydrophobic channel to accommodate myristoyl substrates, and
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also the smaller channels in Sirt2 and, in particular, Sirt3 can
rearrange to efficiently accommodate and hydrolyze longer acy-
lations such as myristoylations23,38,52,53. Sirt4 seems even more
adaptable. Sirt4 structure and mutagenesis data suggest that,
similar to Sirt513, the α5 center contributes to acyl recognition,
but in Sirt4 even the remote α5 N-terminus influences acyl
binding. Furthermore, the α5 center is connected via an Arg107/
Asp203 salt bridge to the Sirt4-loop, an isoform-specific element
of the Sirt4 acyl site, and the Sirt4-loop further to the nucleotide
binding loop through the packing of Pro200 on the auto-
inhibitory Tyr73. The Sirt4-loop assumes at least two states in our
structures and for productive NAD+ binding it indeed has to
rearrange (Supplementary Figs. 2e, 3c)—possibly triggered by a
yet to be identified activator in a physiological setting—which will
induce conformational changes in the acyl site. Shifting Asp201
away from the conventional acyl binding pocket should support
binding of dicarboxyl substrates such as HMG-ylations. A com-
plete loop release, possibly, would open an area accommodating
longer acyls in other isoforms53 and could extend the observed
Sirt4 deoctanoylation activity to longer modifications. Interest-
ingly, Sirt4 accommodates extended lipoyl modifications as sub-
strates despite its length restriction for fatty acids, likely by
exploiting a Sirt4-specific channel branching off from the con-
ventional acyl pocket. The bulkier lipoyl group might exploit this
channel better than slim alkyl chains, and the two acyl sites might
serve, alternatively or even in combination, to expand the acyl
substrate spectrum of Sirt4. Interestingly, a lipoyl moiety would
also fit into the Sirt4-specific channel coming from outside, as a
target label in analogy to the bacterial sirtuin SirTM, which ADP-
ribosylates targets only after their lipoylation35, or as a potential
regulatory metabolite (this study). Sirt4 substrate selection indeed
appears dominated by KM, and its de-HMG-ylation activity is still
slightly lower than major activities of other sirtuin isoforms. Our
comparison of HMG-peptides indicates a relevance for the sub-
strate sequence, consistent with Sirt4 deacetylation studies1,
indicating that better de-HMG-ylation substrates might exist.
Sequence differences might in fact account for our higher Sirt4-
dependent delipoylation and Sirt5-dependent de-HMG-ylation
activity compared to other studies10,32. It will be interesting to see
whether better Sirt4 substrate sequences or acylations can be
identified, and further mechanistic studies, supported by our
structural data, should enable a full understanding of Sirt4-loop
and acyl channel, their substrate adaptations, and possible
external triggers that would regulate Sirt4.
Our Sirt4 substrates and assays enabled analyzes on drug
effects and physiological Sirt4 regulators. The continuous coupled
assay allows excellent quantification27, and the FdL assay pro-
vides a sensitive set-up that is easily parallelized for screening
campaigns19. Using these assays, we find a very potent NAM
inhibition for Sirt4, which renders it the isoform most sensitive to
NAM regulation so far46,54. Physiological NAM concentrations
are assumed to reach up to 100 μM54, which would inhibit Sirt4
almost completely, and in vivo Sirt4 activity will thus strongly
depend on NAM levels. It will be interesting to see how Sirt4
contributes to the physiological effects of NAM. We further find
that Sirt4 activity seems sensitive to physiological NADH levels or
the NAD+/NADH ratio. Sirtuin regulation by NADH or NAD
+/NADH had been suggested based on inhibitory NADH effects
on other isoforms but was discarded due to its weak potency
(IC50≥ 1.3 mM; Ki≥ 0.7 mM), which rules out significant in vivo
effects at assumed NADH concentrations (~30 μM in mito-
chondria) and NAD+/NADH ratios (10:1 and higher)47,48. We
now find an at least one order of magnitude higher NADH
sensitivity for Sirt4, which causes significant effects under such
conditions, and it will be exciting to see how this Sirt4-specific
regulation contributes to its function. Mechanistically, NADH
likely inhibits through nucleotide site binding in an extended,
non-productive conformation also observed for NAD+ under
certain conditions25 (Supplementary Fig. 3c). It places the NAM
moiety outside the C-pocket—which prefers oxidized nucleotide
due to its conserved negative charge—into regions that show
positive electrostatic potential, in particular in Sirt4, which favors
NADH over NAD+. Assays and structural insights also provide a
basis for Sirt4 modulator development. The identified nucleotide
binding site differences should enable Sirt4-specific inhibition, for
example through Ex-527 derivatives that can enter Sirt4’s tigh-
tened C-site. The particular Sirt4 acyl site could be exploited with
thio-DMS-Lys, analog to the alkylimidate forming thio-acetyl
peptides for deacetylases25, and the additional Sirt4 channel
provides another docking site for specific small molecule inhibi-
tors and possibly also activators. Such Sirt4 modulators would be
excellent tools for physiological studies and lead compounds for
drug development, for example for diabetes treatment7.
Methods
Chemicals. If not stated otherwise, chemicals were from Sigma (St. Louis, MO,
USA).
Expression and purification of Sirt4 and Sirt5 proteins. hSirt4(25–314) in
pQE30 coding for an N-terminal His6-tag, and xSirt4(32–315) and zSirt4(29–310)
in a modified pET-19b coding for an N-terminal His6-SUMO-tag (see Supple-
mentary Table 1 for primer sequences), were expressed in Escherichia coli
CodonPlus(DE3) (Agilent, Santa Clara, CA, USA) in LB medium supplemented
with 100 µM zinc acetate. Cells were resuspended in 50 mM Tris/HCl pH 7.5, 200
mM NaCl (and 20% glycerol for xSirt4) and lysed by adding lysozyme and sodium
desoxycholate and subsequent pressure homogenization in an Emulsiflex-C5
(Avestin, Ottawa, Canada). After centrifugation (75,000×g, 4 °C, 1 h), supernatants
were incubated for 1 h with NiNTA beads in presence of 10 mM imidazole. After
transfer in a column, the resin was washed with 20 column volumes (CV) 50 mM
Tris/HCl pH 7.5, 500 mM NaCl and 20 CV 50mM Tris/HCl pH 7.5, 200 mM
NaCl, 10 mM imidazole, and the protein eluted with 50 mM Tris/HCl pH 7.5, 200
mM NaCl, 250 mM imidazole.
For hSirt4(25–314), the buffer of the eluted protein was changed to 50 mM Tris/
HCl pH 7.5, 30 mM NaCl in a HiPrep Desalting Column (GE Healthcare, Chicago,
IL, USA) and the sample applied to a SOURCE15S cation exchange column (GE
Healthcare). The proteins were eluted in a linear gradient 30–1000 mM NaCl and
Sirt4 fractions were pooled and diluted fivefold with 50 mM Tris/HCl pH 7.5. Sirt4
was then loaded on a HiTrap Heparin column (GE Healthcare) and eluted with a
linear gradient 30–1000 mM NaCl. The protein was concentrated to ~1mgml−1 in
a Microsep concentrator (Pall Corporation, Port Washington, NY, USA), flash-
frozen in liquid nitrogen, and stored at −80 °C.
For xSirt4(32–315) and zSirt4(29–310) eluted from the NiNTA material, the
buffer was changed to 50 mM Tris/HCl pH 7.5, 200 mM NaCl, (supplemented with
20% glycerol for xSirt4) in a HiPrep Desalting column and subjected to Senp2-
proteolysis for 30 min on ice. The protein was loaded on a HisTrap HP 1 mL
column (GE Healthcare) and eluted with 50 mM Tris/HCl pH 7.5, 200 mM NaCl,
30–50 mM imidazole. It was subsequently subjected to gel filtration on a Superdex
75 10/300 GL (xSirt4) or Superdex 200 10/300 GL (zSirt4) column (both GE
Healthcare) in 25 mM Tris/HCl pH 7.5, 150 mM NaCl (+20 % glycerol for xSirt4),
concentrated in a Microsep concentrator, flash-frozen in liquid nitrogen, and
stored at −80 °C. xSirt4 single-site variants were generated using the QuickChange
protocol (see Supplementary Table 1 for primer sequences) and verified by DNA
sequencing, and the proteins were produced as described for wild-type xSirt4.
zSirt5(30–298) was expressed in E.coli and purified through Talon affinity
chromatography, TEV-proteolysis, reverse affinity chromatography, and gel
filtration on a Sephacryl S-200 column15.
Synthesis of Lys- and peptide-based substrates. HMG-ylated peptides CPS1
(Bz-GVL(acyl-K)EYGV-NH2), MCD (Ac-TSYLGS(HMG-K)IIKASE-NH2), and
NNT (Ac-NITKLL(HMG-K)AISPDK-NH2) were synthesized using Fmoc-based
solid-phase peptide synthesis protocols. Fmoc-Lys(Nosyl)-OH was used as building
block enabling selective on resin deprotections and acylations using HMG-
anhydride. As acyl peptide library, the panel of acyl CPS1-Lys527 peptides
described in ref. 15 was used and extended through analog synthesis of β-Ala-
CPS1, γ-aminobutyryl-CPS1, 6-aminocaproyl-CPS1, butyryl-CPS1, octanoyl-CPS1,
lipoyl-CPS1, and biotinyl-CPS1.
The Sirt4 substrate Z-Lys(HMG)-AMC (MC3659; 5-(((S)−5-(((benzyloxy)
carbonyl)amino)-6-((4-methyl-2-oxo-2H-chromen-7-yl)amino)-6-oxohexyl)
amino)-3-hydroxy-3-methyl-5-oxopentanoic acid) was synthesized by reaction
between the (S)-benzyl (6-amino-1-((4-methyl-2-oxo-2H-chromen-7-yl)amino)-1-
oxohexan-2-yl)carbamate (Z-Lys-AMC), prepared as reported in literature55, and
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the commercially available 3-hydroxy-3-methylglutaric (HMG) anhydride in dry
THF in the presence of DIPEA at room temperature (Supplementary Fig. 5). All
chemicals were purchased from Aldrich Chimica, Milan (Italy), and were of the
highest purity. Z-Lys-AMC (170 mg, 0.388 mmol) was dissolved at 0 °C in 4 mL
dry THF together with diisopropylethylamine (DIPEA) (140 μL, 0.777 mmol)
under nitrogen atmosphere. A solution of 3-hydroxy-3-methylglutaric anhydride
(67 mg, 0.777 mmol) in dry THF (4 mL) was added dropwise at 0 °C, and the
resulting mixture was left under stirring at room temperature overnight. At the end
of the reaction, water (10 mL) was added, the resulting mixture was made acidic
(pH ∼2) with potassium bisulphate 1M and then extracted with ethyl acetate (6 ×
10 mL). The collected organic phases were washed with brine (2 mL), dried, and
concentrated under reduced pressure to provide a crude residue that was purified
by a silica gel flash chromatography (SNAP 25, Biotage Isolera One) using a linear
gradient of methanol (3–25%) in chloroform, giving the expected compound Z-Lys
(HMG)-AMC as a white solid, with a yield of 72%. Melting point was determined
on a Buchi 530 melting point apparatus and is uncorrected. 1H- and 13C-NMR
spectra were recorded at 400MHz (1H) respective 100MHz (13C) on a Bruker AC
400 spectrometer; reporting chemical shifts in δ (p.p.m.) units relative to the
internal reference tetramethylsilane (Me4Si). All compounds were routinely
checked by TLC and 1H-NMR. TLC was performed on aluminum-backed silica gel
plates (Merck DC, Alufolien Kieselgel 60 F254) with spots visualized by UV light.
Yield of reaction refers to the purified product. Mass spectrum was recorded on an
API-TOF Mariner by Perspective Biosystem (Stratford, TX, USA), and samples
were injected by a Harvard pump, using a flow rate of 5−10 μL min−1, in the
Electrospray system. Elemental analysis was performed by a PE 2400 (Perkin-
Elmer) analyzer and has been used to determine purity of the described compound,
which is >95%. Analytical result is within ±0.40% of the theoretical value.
mp 128–129 °C; yield 72%. 1H-NMR (DMSO) δ 1.18 (s, 3H, C(OH)CH3),
1.32–1.41 (m, 4H, CHCH2CH2CH2CH2NH), 1.61–1.67 (m, 2H,
CHCH2CH2CH2CH2NH), 2.33 (s, 2H, C(OH)(CH3)CH2CONHCH2), 2.38–2.41
(m, 5H, CH2COOH and coumarin-CH3), 3.04 (m, 2H, CH2CONHCH2), 4.15 (m,
1H, α-CH), 5.04 (s, 2H, OCH2Ph), 6.28 (s, 1H, C–H coumarin), 7.18–7.37 (m, 5H,
C–H phenyl ring), 7.51–7.54 (m, 1H, C–H coumarin), 7.67 (m, 1H, C–H
coumarin), 7.73 (d, 1H, Z–NHCHCO), 7.80 (bs, 1H, C–H coumarin), 8.01 (t, 1H,
CH2CONHCH2), 10.61 (bs, 1H, CONH-coumarin). 13C-NMR (DMSO) δ: 174.2,
172.6, 170.9, 161.4, 156.5, 154.2, 153.5, 142.5, 136.8, 128.6 (2C), 128.2 (2C), 127.8,
124.5, 116.7, 112.5, 110.7, 105.2, 71.5, 66.8, 54.1, 47.6, 46.9, 39.1, 30.5, 29.7, 27.4,
22.5, 18.9. Anal. (C30H35N3O9) Calcd. (%): C, 61.95; H, 6.07; N, 7.22. Found (%): C,
62.03; H, 6.05; N, 7.19. MS (ESI), m/z: 580 (M−H)−.
CypA modification and de-HMG-ylation and intact protein MS. The recombi-
nant CypA was prepared through expression of a full-length CypA construct in
pQE70 (Qiagen) in E. coli M15 cells and purification by ion exchange chromato-
graphy on Fractogel EMD DEAE-650(M), Fractogel TSK AF-Blue, and Fractogel
SO3–650(M) (Merck Millipore)29. CypA protein (0.4 mgml−1) was modified using
8 mM HMG-CoA in 100 mM Tris-HCl buffer pH 8.3 at 37 °C for 4 h. Formation of
HMG-ylated protein was confirmed by peptide-MS analyzes after tryptic digest29,
and by intact HMG-CypA mass analyzes through HPLC-coupled ESI-MS56. For
intact mass determination, 25 µM HMG-CypA in 10 mM Tris/HCl pH 7.5, 50 mM
NaCl was HPLC-separated with the setting described below for peptide MS, using a
30 min gradient from 1 to 55% buffer B (90% ACN, 9.9% H2O, 0.1% FA; buffer A:
5% ACN, 94.9% H2O, 0.1% FA) followed by 1 min of 55–90% buffer B with 70 µL
min−1 flow-rate. MS-analyzes were done with the settings described for peptide
assays (below), except that the IntactProtein script was activated, which reduces
CEM to 100. Acquired data were extracted with PeakView and deconvoluted in
MassLynx in the range of 950–1500 m/z using the MaxEnt I algorithm to a reso-
lution of 1 Da. Peak intensity values were recorded and overlaid using MassLynx.
For MS-based CypA deacylation analyzes, 50 µM HMG-modified CypA was
incubated for 2 h at 37 °C with 20 µM hSirt4 and 2 mM NAD+, as well as 0.5 mg
mL–1 nicotinamidase to prevent Sirt4-inhibition by released nicotinamide. Control
reactions without Sirt4 were incubated for 22 h. All reactions were stopped through
mixing 1:1 with 0.5% TFA and analyzed by ESI-MS as described above56. CypA de-
HMG-ylations in the coupled continuous assay were performed as described for
peptide-based assays.
Peptide- and FdL-based activity assays. The coupled continuous assay was
performed as reported27. Briefly, assays in 20 mM sodium phosphate buffer pH 7.8
contained 5 µM hSirt4 or 3–5 µM xSirt4, 0.05 mgml−1 nicotinamidase, 2 Uml–1
GDH, 3.3 mM a-ketoglutarate, 0.2 mM NADPH, 10% DMSO, and NAD+ at 2 mM
or as indicated, and substrate peptide at 500 µM or as indicated. Reactions were
monitored in microplates at room temperature for 1 h through absorption mea-
surements at 340 nm in a LAMBDAScan plate reader (MWG Biotech, Ebersberg,
Germany).
The Fluor-de-Lys (FdL) assay was performed at 37 °C in 25 mM Tris/HCl, 150
mM NaCl with 1 µM hSirt4, 500 µMHMG-FdL substrate and 500 µMNAD+. After
20 min, developer solution (2 mM NAM and 10mgmL−1 trypsin) in assay buffer
was added 1:1 and samples were incubated for 45 min at room temperature.
Fluorescence was measures using a FluoDia T70 with excitation wavelength 365
nm and emission wavelength 465 nm.
For MS and UV analyzes of deacylation reactions, samples were prepared as
described for the coupled continuous assay, stopped by mixing 1:1 with 0.5% TFA
after 0 and 60 min, diluted to 20 µM peptide using 0.1% FA, and analyzed by
HPLC-separation using a Shimadzu Prominence UFLC (Shimadzu, Duisburg,
Germany) coupled to ESI-MS and UV detection. Samples were washed on a
Piccolo Proto 200 C4 5 μm 2.5 × 0.5 mm trap column (Higgins Analytical,
Mountain View, California) and subsequently subjected to a Jupiter C4 5 μm 300 Å
150 × 1mm analytical column (Phenomenex, Torrance, California) for reversed
phase separation, with 99.9% H2O, 0.1% TFA as buffer A and 99.9% ACN, 0.1%
TFA as buffer B. Peptides were eluted over a 20 min gradient from 1 to 55% buffer
B, followed by 1 min from 55 to 90% buffer B with 70 µLmin−1 flow-rate. UV-
detection was done using a Shimadzu SPD-20A detector at 280 nm. MS analysis
was performed by ESI-TOF-MS on an AB Sciex TripleTOF 5600+ mass
spectrometer (Sciex, Darmstadt, Germany) with a DuoSpray Ion Source using the
following settings: floating voltage of 5500 V and declustering potential of 100 with
one TOF experiment summing over four time bins. We detected in a mass range
from 300 to 2500 m/z. XIC of substrate and product peptides were extracted using
their respective mass in singly, doubly, or triply charged state within a window of
0.2 m/z in PeakView version 1.2.0.3.
Thermal denaturation shift assays. Thermal shift assays were performed in 96-
well PCR plates using 3 µM xSirt4 (32–315) or 3 µM zSirt4 (29–310) and SYPRO
orange (Thermo Fisher, Waltham, MA, USA) covered with 15 µL mineral oil.
Heating and fluorescence measurements were performed in a FluoDia T70 with 1 K
steps from 20 to 73 °C (excitation: 465 nm, emission: 580 nm). The data were
analyzed in GraFit (Erithacus Software Ltd, Horley, UK) by nonlinear fitting using
a two state model.
Statistical information. Data points for activity assays were determined in
duplicates, and all experiments were done in at least two repetitions.
Sirt4 crystallization and structure determination. xSirt4(32–315) protein (5mg
ml−1 in 25mM Tris/HCl 7.5, 150mM NaCl, 20% glycerol) was incubated with 10
mM ADPr (xSirt4/ADPr complex) or 1 mM thioacetyl H3K9 peptide and 5mM
NAD+ (xSirt4/thioacetyl-ADPr complex) on ice for 30min. The xSirt4 complexes
crystallized at 4 °C in sitting drops (1:1 ratio protein to reservoir solution) with 100
mM BICINE pH 8.5, 20% PEG6000 (xSirt4/ADPr) or 500mM Na/K-tartrate, 0.5%
PEG5000MME, 100mM TRIS/HCl pH 8.5 (xSirt4/thioacetyl-ADPr) as reservoir.
zSirt5 (10mgmL–1 in 20mM TRIS/HCl pH 8.5, 150mM NaCl) was incubated with
1mM HMG-CPS1-peptide (10% v/v DMSO final concentration) on ice for 30min
and crystallized in sitting drops at 20 °C using 20% PEG3350, 100mM HEPES pH 7.6
as reservoir solution. Crystals appeared within 3 days (xSirt4) or 2 weeks (zSirt5), were
transferred to a drop of reservoir solution supplemented with the co-crystallization
ligand and 25% glycerol for 1min, and flash-frozen in liquid nitrogen.
Data collection was done at BESSY II beamline MX14.1 (operated by the
Helmholtz Zentrum Berlin, Germany) using a wavelength of 0.912 Å and a Pilatus
6M detector (Dectris, Baden, Switzerland). Indexing, scaling and merging of
diffraction data was performed with XDS57. Structures were solved by molecular
replacement with PHASER58 using as a search model a Sir2Af1/peptide complex
(PDB-Code 4TWI59) for xSirt4/ADPr, this initial xSirt4 structure for xSirt4/
thioacetyl-ADPr, and a zSirt5/peptide complex (PDB ID 4UTV15) for zSirt5/HMG-
CPS1. Refinement was performed with Refmac560, using partially anisotropic B-
factors and TLS for the protein chain and the Zn ion for the xSirt4/ADPr complex.
Models were built and validated using Coot61 and structure figures were generated
with PyMol (Schrödinger, LLC). Docking of Lipoyl-Lys in the xSirt4/ADPr active-
site was done with LeadIT (BiosolveIT GmbH, Sankt Augustin, Germany).
Sequence alignments and phylogenetic trees. Structure-based sequence align-
ments were created using STRAP with the integrated Aligner3D algorithm62, and
manual editing and phylogenetic tree generation were done with BioEdit63. Con-
servation levels were mapped on the xSirt4 structure surface using ConSurf64.
Data availability. Structure factors and refined structures have been deposited
with the Protein Data Bank (http://www.rcsb.org/pdb) under accession codes 5OJ7
(xSirt4/ADPr), 5OJN (xSirt4/thioacetyl-ADPr), and 5OJO (zSirt5/HMG-CPS1).
Other data are available from the corresponding author upon reasonable request.
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